Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)
An 11q23 abnormality presents in approximately 5% of adults with acute myeloid leukemia (AML) and is associated with adverse outcomes even after allogeneic hematopoietic cell transplantation (allo-HCT). To evaluate the outcomes and prognostic factors following allo-HCT for adult AML with 11q23 abnor...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2018-11, Vol.97 (11), p.2173-2183 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2183 |
|---|---|
| container_issue | 11 |
| container_start_page | 2173 |
| container_title | Annals of hematology |
| container_volume | 97 |
| creator | Konuma, Takaaki Mizuno, Shohei Kondo, Tadakazu Yamaguchi, Hiroki Fukuda, Takahiro Uchida, Naoyuki Najima, Yuho Kanamori, Heiwa Ota, Shuichi Nakamae, Hirohisa Nakamae, Mika Mizuno, Ishikazu Sugita, Junichi Onishi, Yasushi Yokota, Akira Takahashi, Satoshi Kanda, Yoshinobu Ichinohe, Tatsuo Atsuta, Yoshiko Yano, Shingo |
| description | An 11q23 abnormality presents in approximately 5% of adults with acute myeloid leukemia (AML) and is associated with adverse outcomes even after allogeneic hematopoietic cell transplantation (allo-HCT). To evaluate the outcomes and prognostic factors following allo-HCT for adult AML with 11q23 abnormality, we retrospectively analyzed the Japanese registration data of 322 adult AML patients with 11q23 abnormality who had received allo-HCT between 1990 and 2014. In total, the disease status at HCT was first complete remission (CR1) in 159 (49%) patients. The probability of overall survival and the cumulative incidence of relapse at 3 years were 44 and 44%, respectively. In the multivariate analysis, disease status beyond CR1 at the time of HCT was significantly associated with a higher overall mortality and relapse. The 11q23 fusion partner did not have a significant impact on survival. We also evaluated the prognostic value of minimal residual disease (MRD) status at HCT on transplant outcomes among hematological CR patients. MRD status at HCT was the significant prognostic indicator for hematological relapse and survival. These data suggested that allo-HCT offered a curative option for adult AML with 11q23 abnormality. Pretransplant MRD status was the significant prognostic indicator for relapse and survival in CR patients. |
| doi_str_mv | 10.1007/s00277-018-3419-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2066475625</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2066475625</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-5cd3eefd7a6647a9916d20927444f6d2325428de5e81b03b56d0d050838df4223</originalsourceid><addsrcrecordid>eNp1ks1uEzEUhS0EoqHwAGyQJTZlMeDf-WEXRdBQBbFoEMuRM76TuJ2xp7anKI_NG-BpEhCV8Ma2fM7no6uD0GtK3lNCig-BEFYUGaFlxgWtMvoEzajgLCOyFE_RjFS8ymRaZ-hFCDeEUFYK9hydsaoqSlbmM_Rr3nVuCxZMg3fQq-gGZyCmWwNdh6NXNgydslFF4yw2Fis9dhGrZoyA-z10zmjcwXgLvVH4p4k7TOkd41htrPO96kzcf8QKe4jehQGaaO4BhzjqPXYtjjvA8wfi_IH49UhcnYg_nL81dosvvRuHk-NKDcria9ekqHvcOo-X_2RfTNnXj7JfXF0vF-t3L9GzVnUBXh33c_T986f1Ypmtvl1-WcxXWcMLFjPZaA7Q6kLluShUVdFcM1KxQgjRpiNnUrBSg4SSbgjfyFwTTSQpealbwRg_RxcH7uDd3Qgh1r0J01CVBTeGmpEJLHMmk_TtI-mNG71N6SaVkIUUgiYVPaiaNMjgoa0Hb3rl9zUl9dSH-tCHOvWhnvpQT543R_K46UH_cZwKkATsIAjpyW7B__36_9Tfjw_ECw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2064575441</pqid></control><display><type>article</type><title>Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)</title><source>SpringerLink Journals - AutoHoldings</source><creator>Konuma, Takaaki ; Mizuno, Shohei ; Kondo, Tadakazu ; Yamaguchi, Hiroki ; Fukuda, Takahiro ; Uchida, Naoyuki ; Najima, Yuho ; Kanamori, Heiwa ; Ota, Shuichi ; Nakamae, Hirohisa ; Nakamae, Mika ; Mizuno, Ishikazu ; Sugita, Junichi ; Onishi, Yasushi ; Yokota, Akira ; Takahashi, Satoshi ; Kanda, Yoshinobu ; Ichinohe, Tatsuo ; Atsuta, Yoshiko ; Yano, Shingo</creator><creatorcontrib>Konuma, Takaaki ; Mizuno, Shohei ; Kondo, Tadakazu ; Yamaguchi, Hiroki ; Fukuda, Takahiro ; Uchida, Naoyuki ; Najima, Yuho ; Kanamori, Heiwa ; Ota, Shuichi ; Nakamae, Hirohisa ; Nakamae, Mika ; Mizuno, Ishikazu ; Sugita, Junichi ; Onishi, Yasushi ; Yokota, Akira ; Takahashi, Satoshi ; Kanda, Yoshinobu ; Ichinohe, Tatsuo ; Atsuta, Yoshiko ; Yano, Shingo ; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation</creatorcontrib><description>An 11q23 abnormality presents in approximately 5% of adults with acute myeloid leukemia (AML) and is associated with adverse outcomes even after allogeneic hematopoietic cell transplantation (allo-HCT). To evaluate the outcomes and prognostic factors following allo-HCT for adult AML with 11q23 abnormality, we retrospectively analyzed the Japanese registration data of 322 adult AML patients with 11q23 abnormality who had received allo-HCT between 1990 and 2014. In total, the disease status at HCT was first complete remission (CR1) in 159 (49%) patients. The probability of overall survival and the cumulative incidence of relapse at 3 years were 44 and 44%, respectively. In the multivariate analysis, disease status beyond CR1 at the time of HCT was significantly associated with a higher overall mortality and relapse. The 11q23 fusion partner did not have a significant impact on survival. We also evaluated the prognostic value of minimal residual disease (MRD) status at HCT on transplant outcomes among hematological CR patients. MRD status at HCT was the significant prognostic indicator for hematological relapse and survival. These data suggested that allo-HCT offered a curative option for adult AML with 11q23 abnormality. Pretransplant MRD status was the significant prognostic indicator for relapse and survival in CR patients.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-018-3419-1</identifier><identifier>PMID: 29978286</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Hematology ; Leukemia ; Medical prognosis ; Medicine ; Medicine & Public Health ; Oncology ; Original Article ; Stem cell transplantation ; Transplants & implants</subject><ispartof>Annals of hematology, 2018-11, Vol.97 (11), p.2173-2183</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2018</rights><rights>Annals of Hematology is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-5cd3eefd7a6647a9916d20927444f6d2325428de5e81b03b56d0d050838df4223</citedby><cites>FETCH-LOGICAL-c372t-5cd3eefd7a6647a9916d20927444f6d2325428de5e81b03b56d0d050838df4223</cites><orcidid>0000-0002-1496-376X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-018-3419-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-018-3419-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29978286$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Konuma, Takaaki</creatorcontrib><creatorcontrib>Mizuno, Shohei</creatorcontrib><creatorcontrib>Kondo, Tadakazu</creatorcontrib><creatorcontrib>Yamaguchi, Hiroki</creatorcontrib><creatorcontrib>Fukuda, Takahiro</creatorcontrib><creatorcontrib>Uchida, Naoyuki</creatorcontrib><creatorcontrib>Najima, Yuho</creatorcontrib><creatorcontrib>Kanamori, Heiwa</creatorcontrib><creatorcontrib>Ota, Shuichi</creatorcontrib><creatorcontrib>Nakamae, Hirohisa</creatorcontrib><creatorcontrib>Nakamae, Mika</creatorcontrib><creatorcontrib>Mizuno, Ishikazu</creatorcontrib><creatorcontrib>Sugita, Junichi</creatorcontrib><creatorcontrib>Onishi, Yasushi</creatorcontrib><creatorcontrib>Yokota, Akira</creatorcontrib><creatorcontrib>Takahashi, Satoshi</creatorcontrib><creatorcontrib>Kanda, Yoshinobu</creatorcontrib><creatorcontrib>Ichinohe, Tatsuo</creatorcontrib><creatorcontrib>Atsuta, Yoshiko</creatorcontrib><creatorcontrib>Yano, Shingo</creatorcontrib><creatorcontrib>Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation</creatorcontrib><title>Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>An 11q23 abnormality presents in approximately 5% of adults with acute myeloid leukemia (AML) and is associated with adverse outcomes even after allogeneic hematopoietic cell transplantation (allo-HCT). To evaluate the outcomes and prognostic factors following allo-HCT for adult AML with 11q23 abnormality, we retrospectively analyzed the Japanese registration data of 322 adult AML patients with 11q23 abnormality who had received allo-HCT between 1990 and 2014. In total, the disease status at HCT was first complete remission (CR1) in 159 (49%) patients. The probability of overall survival and the cumulative incidence of relapse at 3 years were 44 and 44%, respectively. In the multivariate analysis, disease status beyond CR1 at the time of HCT was significantly associated with a higher overall mortality and relapse. The 11q23 fusion partner did not have a significant impact on survival. We also evaluated the prognostic value of minimal residual disease (MRD) status at HCT on transplant outcomes among hematological CR patients. MRD status at HCT was the significant prognostic indicator for hematological relapse and survival. These data suggested that allo-HCT offered a curative option for adult AML with 11q23 abnormality. Pretransplant MRD status was the significant prognostic indicator for relapse and survival in CR patients.</description><subject>Hematology</subject><subject>Leukemia</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Stem cell transplantation</subject><subject>Transplants & implants</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp1ks1uEzEUhS0EoqHwAGyQJTZlMeDf-WEXRdBQBbFoEMuRM76TuJ2xp7anKI_NG-BpEhCV8Ma2fM7no6uD0GtK3lNCig-BEFYUGaFlxgWtMvoEzajgLCOyFE_RjFS8ymRaZ-hFCDeEUFYK9hydsaoqSlbmM_Rr3nVuCxZMg3fQq-gGZyCmWwNdh6NXNgydslFF4yw2Fis9dhGrZoyA-z10zmjcwXgLvVH4p4k7TOkd41htrPO96kzcf8QKe4jehQGaaO4BhzjqPXYtjjvA8wfi_IH49UhcnYg_nL81dosvvRuHk-NKDcria9ekqHvcOo-X_2RfTNnXj7JfXF0vF-t3L9GzVnUBXh33c_T986f1Ypmtvl1-WcxXWcMLFjPZaA7Q6kLluShUVdFcM1KxQgjRpiNnUrBSg4SSbgjfyFwTTSQpealbwRg_RxcH7uDd3Qgh1r0J01CVBTeGmpEJLHMmk_TtI-mNG71N6SaVkIUUgiYVPaiaNMjgoa0Hb3rl9zUl9dSH-tCHOvWhnvpQT543R_K46UH_cZwKkATsIAjpyW7B__36_9Tfjw_ECw</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Konuma, Takaaki</creator><creator>Mizuno, Shohei</creator><creator>Kondo, Tadakazu</creator><creator>Yamaguchi, Hiroki</creator><creator>Fukuda, Takahiro</creator><creator>Uchida, Naoyuki</creator><creator>Najima, Yuho</creator><creator>Kanamori, Heiwa</creator><creator>Ota, Shuichi</creator><creator>Nakamae, Hirohisa</creator><creator>Nakamae, Mika</creator><creator>Mizuno, Ishikazu</creator><creator>Sugita, Junichi</creator><creator>Onishi, Yasushi</creator><creator>Yokota, Akira</creator><creator>Takahashi, Satoshi</creator><creator>Kanda, Yoshinobu</creator><creator>Ichinohe, Tatsuo</creator><creator>Atsuta, Yoshiko</creator><creator>Yano, Shingo</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1496-376X</orcidid></search><sort><creationdate>20181101</creationdate><title>Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)</title><author>Konuma, Takaaki ; Mizuno, Shohei ; Kondo, Tadakazu ; Yamaguchi, Hiroki ; Fukuda, Takahiro ; Uchida, Naoyuki ; Najima, Yuho ; Kanamori, Heiwa ; Ota, Shuichi ; Nakamae, Hirohisa ; Nakamae, Mika ; Mizuno, Ishikazu ; Sugita, Junichi ; Onishi, Yasushi ; Yokota, Akira ; Takahashi, Satoshi ; Kanda, Yoshinobu ; Ichinohe, Tatsuo ; Atsuta, Yoshiko ; Yano, Shingo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-5cd3eefd7a6647a9916d20927444f6d2325428de5e81b03b56d0d050838df4223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Hematology</topic><topic>Leukemia</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Stem cell transplantation</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Konuma, Takaaki</creatorcontrib><creatorcontrib>Mizuno, Shohei</creatorcontrib><creatorcontrib>Kondo, Tadakazu</creatorcontrib><creatorcontrib>Yamaguchi, Hiroki</creatorcontrib><creatorcontrib>Fukuda, Takahiro</creatorcontrib><creatorcontrib>Uchida, Naoyuki</creatorcontrib><creatorcontrib>Najima, Yuho</creatorcontrib><creatorcontrib>Kanamori, Heiwa</creatorcontrib><creatorcontrib>Ota, Shuichi</creatorcontrib><creatorcontrib>Nakamae, Hirohisa</creatorcontrib><creatorcontrib>Nakamae, Mika</creatorcontrib><creatorcontrib>Mizuno, Ishikazu</creatorcontrib><creatorcontrib>Sugita, Junichi</creatorcontrib><creatorcontrib>Onishi, Yasushi</creatorcontrib><creatorcontrib>Yokota, Akira</creatorcontrib><creatorcontrib>Takahashi, Satoshi</creatorcontrib><creatorcontrib>Kanda, Yoshinobu</creatorcontrib><creatorcontrib>Ichinohe, Tatsuo</creatorcontrib><creatorcontrib>Atsuta, Yoshiko</creatorcontrib><creatorcontrib>Yano, Shingo</creatorcontrib><creatorcontrib>Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Konuma, Takaaki</au><au>Mizuno, Shohei</au><au>Kondo, Tadakazu</au><au>Yamaguchi, Hiroki</au><au>Fukuda, Takahiro</au><au>Uchida, Naoyuki</au><au>Najima, Yuho</au><au>Kanamori, Heiwa</au><au>Ota, Shuichi</au><au>Nakamae, Hirohisa</au><au>Nakamae, Mika</au><au>Mizuno, Ishikazu</au><au>Sugita, Junichi</au><au>Onishi, Yasushi</au><au>Yokota, Akira</au><au>Takahashi, Satoshi</au><au>Kanda, Yoshinobu</au><au>Ichinohe, Tatsuo</au><au>Atsuta, Yoshiko</au><au>Yano, Shingo</au><aucorp>Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2018-11-01</date><risdate>2018</risdate><volume>97</volume><issue>11</issue><spage>2173</spage><epage>2183</epage><pages>2173-2183</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>An 11q23 abnormality presents in approximately 5% of adults with acute myeloid leukemia (AML) and is associated with adverse outcomes even after allogeneic hematopoietic cell transplantation (allo-HCT). To evaluate the outcomes and prognostic factors following allo-HCT for adult AML with 11q23 abnormality, we retrospectively analyzed the Japanese registration data of 322 adult AML patients with 11q23 abnormality who had received allo-HCT between 1990 and 2014. In total, the disease status at HCT was first complete remission (CR1) in 159 (49%) patients. The probability of overall survival and the cumulative incidence of relapse at 3 years were 44 and 44%, respectively. In the multivariate analysis, disease status beyond CR1 at the time of HCT was significantly associated with a higher overall mortality and relapse. The 11q23 fusion partner did not have a significant impact on survival. We also evaluated the prognostic value of minimal residual disease (MRD) status at HCT on transplant outcomes among hematological CR patients. MRD status at HCT was the significant prognostic indicator for hematological relapse and survival. These data suggested that allo-HCT offered a curative option for adult AML with 11q23 abnormality. Pretransplant MRD status was the significant prognostic indicator for relapse and survival in CR patients.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>29978286</pmid><doi>10.1007/s00277-018-3419-1</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-1496-376X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2018-11, Vol.97 (11), p.2173-2183 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2066475625 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Hematology Leukemia Medical prognosis Medicine Medicine & Public Health Oncology Original Article Stem cell transplantation Transplants & implants |
| title | Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T22%3A19%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Allogeneic%20hematopoietic%20cell%20transplantation%20in%20adult%20acute%20myeloid%20leukemia%20with%2011q23%20abnormality:%20a%20retrospective%20study%20of%20the%20Adult%20Acute%20Myeloid%20Leukemia%20Working%20Group%20of%20the%20Japan%20Society%20for%20Hematopoietic%20Cell%20Transplantation%20(JSHCT)&rft.jtitle=Annals%20of%20hematology&rft.au=Konuma,%20Takaaki&rft.aucorp=Adult%20Acute%20Myeloid%20Leukemia%20Working%20Group%20of%20the%20Japan%20Society%20for%20Hematopoietic%20Cell%20Transplantation&rft.date=2018-11-01&rft.volume=97&rft.issue=11&rft.spage=2173&rft.epage=2183&rft.pages=2173-2183&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-018-3419-1&rft_dat=%3Cproquest_cross%3E2066475625%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2064575441&rft_id=info:pmid/29978286&rfr_iscdi=true |